尽管他汀类药物的使用与肝癌风险之间的关系已被广泛研究，但很少有研究检查其他降胆固醇药物与肝癌风险的关系。作者检查了五类非他汀类药物和肝癌风险。在临床实践研究数据链中进行了包含 3719 例病例和 14,876 例匹配对照的嵌套病例对照。还对 2 型糖尿病和慢性肝病进行了额外的匹配。检查的药物包括胆固醇吸收抑制剂、胆汁酸螯合剂、贝特类药物、烟酸和 omega-3 脂肪酸。条件逻辑回归估计比值比和 95% 置信区间。在总体分析（比值比，0.69；95% 置信区间，0.50-0.96）和基于 2 型糖尿病的分析中，使用胆固醇吸收抑制剂与降低肝癌风险相关和慢性肝病状况。尽管在总体分析中胆汁酸螯合剂的使用与肝癌风险增加相关（比值比，5.31；95%置信区间，3.534-7.97），但基于2型糖尿病和慢性肝病状态的分析结果不一致。其他药物没有观察到相关性。胆固醇吸收抑制剂可能与降低肝癌风险有关。目前的研究仅部分支持胆汁酸螯合剂的使用是否与风险增加相关。© 2024 作者。 《癌症》由 Wiley periodicals LLC 代表美国癌症协会出版。本文由美国政府雇员撰写，他们的作品在美国属于公共领域。

Although the relation between statin use and liver cancer risk has been extensively examined, few studies have examined other cholesterol-lowering medications in relation to liver cancer risk. The authors examined five classes of nonstatin medications and liver cancer risk.A nested case-control including 3719 cases and 14,876 matched controls was conducted within the Clinical Practice Research Datalink. Additional matches on type 2 diabetes and chronic liver disease were also implemented. The medications examined included cholesterol absorption inhibitors, bile acid sequestrants, fibrates, niacin, and omega-3 fatty acids. Conditional logistic regression estimated odds ratios and 95% confidence intervals.Cholesterol absorption inhibitor use was associated with reduced liver cancer risk in the overall analysis (odds ratio, 0.69; 95% confidence interval, 0.50-0.96) and in analyses based on type 2 diabetes and chronic liver disease status. Although bile acid sequestrant use was associated with increased liver cancer risk in the overall analysis (odds ratio, 5.31; 95% confidence interval, 3.534-7.97), the results of the analyses based on type 2 diabetes and chronic liver disease status were inconsistent. No associations were observed for the other medications.Cholesterol absorption inhibitors may be associated with reduced liver cancer risk. Whether bile acid sequestrant use was associated with increased risk was only partially supported in the current study.© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.